{
    "nct_id": "NCT03401788",
    "official_title": "An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma",
    "inclusion_criteria": "* Has a diagnosis of von Hippel Lindau disease, based on a germline VHL alteration\n* Has at least 1 measurable solid RCC tumor and no RCC tumor that requires immediate surgical intervention. The diagnosis of RCC can be radiologic (histologic diagnosis not required). Participants may have VHL disease-associated tumors in other organ systems\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has received prior treatment with belzutifan or another HIF-2Î± inhibitor\n* Has had any systemic anti-cancer therapy (includes anti-vascular endothelial growth factor [VEGF] therapy or any systemic investigational anti-cancer agent)\n* Has an immediate need for surgical intervention for tumor treatment\n* Has evidence of metastatic disease on screening imaging",
    "miscellaneous_criteria": ""
}